Kenvue Prevails in Tylenol 'Rapid Release' Gelcap Class Action Lawsuit
AinvestFriday, Aug 30, 2024 3:06 pm ET

Kenvue Inc., the manufacturer of Tylenol, has successfully defended itself against a lawsuit claiming consumers overpaid for "Rapid Release" gelcaps due to alleged misleading marketing. The gelcaps were found to have a slightly longer dissolve time than tablets. The court ruled that the FDA's regulations on acetaminophen dissolution rates preempted the claims, as the FDA did not recognize the term "rapid release." Kenvue, formerly a part of Johnson & Johnson, is now an independent company.
IntroductionKenvue Inc. (NYSE: KVUE), the newly independent global leader in consumer health, has recently secured a significant legal victory against a consumer lawsuit claiming overpayment for Tylenol's "Rapid Release" gelcaps [1]. The lawsuit, which alleged misleading marketing due to the gelcaps' slightly longer dissolve time than tablets, was dismissed based on the preemption of FDA regulations.
Preemption of FDA Regulations
The U.S. Food and Drug Administration (FDA) has established regulations on acetaminophen dissolution rates, which are the timeframes within which a medication must dissolve to be considered effective [2]. In the case of Kenvue's Tylenol "Rapid Release" gelcaps, the FDA did not recognize the term "rapid release" as a specific category within these regulations [3]. Consequently, the court ruled that the plaintiff's claims were preempted by the FDA's regulations, as they relied on a term not recognized by the regulatory agency.
Implications of the Legal Victory
The legal victory is significant for Kenvue as it reinforces the company's focus on delivering science-backed and effective care solutions to consumers [1]. The ruling also highlights the importance of understanding and complying with FDA regulations in the development and marketing of pharmaceutical products.
As the world's largest pure-play consumer health company, Kenvue is well-positioned to continue its growth and innovation, with a portfolio of iconic brands that are trusted by healthcare professionals and consumers worldwide.
References
[1] Kenvue Inc. "Kenvue Becomes a Fully Independent Company." August 23, 2023. https://www.kenvue.com/media/kenvue-becomes-a-fully-independent-company
[2] U.S. Food and Drug Administration. "Test Methods for Evaluating the Dissolution Rate of Solid Oral Dosage Forms: Final Guidance for Industry." April 2012. https://www.fda.gov/media/115232/download
[3] Reuters. "Kenvue Says U.S. Court Dismisses Tylenol Rapid-Release Lawsuit." August 23, 2023. https://www.reuters.com/business/healthcare-pharmaceuticals/kenvue-says-us-court-dismisses-tylenol-rapid-release-lawsuit-2023-08-23/
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet